Full Description
Despite recent advances in the diagnosis and treatment of symptomatic atherosclerosis, available traditional screening methods for early detection and treatment of asymptomatic coronary artery disease are grossly insufficient and fail to identify the majority of victims prior to the onset of a life-threatening event. In Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment, Dr. Morteza Naghavi and leading authorities from the Society for Heart Attack Prevention and Eradication (SHAPE) present a new paradigm for the screening and primary prevention of asymptomatic atherosclerosis. The text focuses on accurate, yet underutilized, measures of subclinical atherosclerosis, notably coronary artery calcium scanning and carotid intima-media thickness measurement. The authors introduce a comprehensive approach to identifying the vulnerable patients (asymptomatic individuals at risk of a near future adverse event). Additional chapters discuss future directions towards containing the epidemic of atherosclerotic cardiovascular disease using innovative solutions such as preemptive interventional therapies (bioabsorbable stents) for stabilization of vulnerable atherosclerotic plaques, mass unconditional Polypill therapy for population-based risk reduction, and ultimately vaccination strategies to prevent the development of atherosclerosis. Up-to-date and authoritative, Asymptomatic Atherosclerosis: Pathophysiology, Detection, and Treatment is a must-have for any cardiologist or primary care physician who wishes to practice modern preventive cardiology and manage the increasing number of asymptomatic atherosclerotic patients. Outlines more accurate measures of risk (coronary artery calcium and carotid intima-media thickness) than traditional risk factors (total cholesterol, LDL cholesterol, HDL cholesterol) Presents new multipronged strategies to aid in the early detection and treatment of high risk asymptomatic patients
Contents
From the contents
1. Preventive Cardiology: The SHAPE of the Future.- 2. From Vulnerable Plaque to Vulnerable Patient.- 3. Pathology of Vulnerability Caused by High Risk (Vulnerable) Arteries and Plaques.- 4. Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood.- 5. Vulnerability Caused by Arrhythmogenic Vulnerable Myocardium.- 6. Approach to the Identification of the Vulnerable Patient.- Current Screening Guidelines in Primary Prevention.- Burden of Atherosclerotic Cardiovascular Disease. Risk Factors vs Susceptibility vs Vulnerability. Screening for Silent Disease to Prevent Deadly Disease. Screening for Atherosclerosis vs Screening for Risk Factors of Atherosclerosis. Methods for the Detection of Subclinical Atherosclerotic Cardiovascular Disease.- Risk Factors: 7. History of evolution of cardiovascular risk factors and the predictive value of
Traditional Risk Factor-Based Risk Assessment.- 8. Comprehensive Lipid Profiling Beyond LDL.- 9. New Serum Markers of Inflammation and Atherosclerosis.- 10. Genetic Screening and Sudden Cardiac Death.- 11. Genomics and Proteomics: The Role of Contemporary Biomolecular Analysis.- In Advancing the Knowledge of Atherosclerotic Coronary Artery Disease.- 12. Circulating Endothelial Progenitor Cells - Mechanism and Measurements.- 13. Family History: An index of genetic and environmental predisposition to coronary artery disease.- 14. Integration of Markers of Endothelial Activation in Mechanism-based Management of Coronary Artery Disease.- Non Invasive, Non Imaging, Assessment of Atherosclerotic Cardiovascular Disease (ACVD).
